All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 25, 2021
Home » Blogs » BioWorld MedTech Perspectives » The morcellator non-story

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The morcellator non-story

June 1, 2015
By Mark McCarty
No Comments

FBI looks where FDA saw nothing
FBI; Justice going blindly?

We've all heard about the FBI investigation into manufacturers of power morcellators, and much of the coverage comes across as breathlessness in search of a scandal. This story goes back to at least 2006 when Ethicon, the Johnson & Johnson subsidiary that withdrew its morcellators from the market last year, appended product labels to advise physicians of the potential for the spread of uterine neoplasms during morcellation for hysterectomy or fibroid removal.

There are a number of moving parts to this saga, but the nagging question is still that of what prompted the FBI  investigation, and what the answer to that implies about the likely outcome.

Are evil device makers hiding something?

By some estimates, surgeons performed 50,000 morcellations annually before FDA advised the public last year it would "discourage" the procedure, and the agency said it knew of a dozen instances in which morcellation may have spread uterine sarcomas or other cancerous tissues. FDA's latest statement claims that roughly one in 350 women undergoing hysterectomy or myomectomy have undetected/unsuspected disease, but 12 cases would be a lot of under-reporting even if only half such situations led to the spread of a tumor.

Still, we might ask why physicians are slow to abandon morcellation. Good question. According to this information, morcellation is safer than conventional surgical hysterectomy for a large number of women. Funny how nobody in the media is talking about that.

Beyond all that, we have the fact that most doctors will sell out the device maker every time in an effort to sidestep any imputation that patient selection or surgical technique was at fault. Nonetheless, patients are far happier suing some "soulless device maker" rather than "the doctor who saved my life," and there are plenty of attorneys who will go for the deepest pockets even if such a pursuit belies the facts of the case. I've been at this long enough to know that for politicians and the mainstream media, device makers are the default evildoer in this realm, regardless of the facts.

What the beginning tells us about the end

The final piece in this puzzle is how the New Jersey FBI office became involved. I asked FDA about whether it typically forwards such things to the FBI's DoJ overlords rather than the FBI, and all they said was "umm. Errr. Ahhhh." Got the same run-around from the FBI public affairs office when I asked how that agency decides whether to take this kind of case rather than hand it off.

It turns out that the best explanation for the FBI involvement is still that the physician husband of a patient contacted the FBI office in New Jersey persistently, but let's be mindful of something: FDA has yet to allege device makers have been playing games with adverse event data, nor has the agency cited any of them for failure to file medical device reports. Interesting, isn't it?

I make a point of emphasizing this point-of-origin business because there are those who would have the American public believe that FDA's device center is an industry lapdog. Those conspiracy theorists should ask the relatives of the tens of thousands of Americans who are six feet under because of device lag whether they believe the industry lap-dog theory of FDA.

When you add it all up, it's entirely implausible that the FBI field office in New Jersey is taking this up because of any data provided or action taken by FDA. And that, dear reader, tells you everything you need to know about how this story will unwind.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing